Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

NCT01213472 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01213472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01213472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
April 17, 2018
Enrollment
33 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma